查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403508

Capecitabine市場至2030年的預測：按類型、適應症、分銷管道、最終用戶和地區進行的全球分析

Capecitabine Market Forecasts to 2030 - Global Analysis By Type (Generic and Branded), Indication (Breast Cancer, Colorectal Cancer and Other Indications),Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC的資料，2023年全球Capecitabine市場規模為4.3636億美元，預計到2030年將達到6.9613億美元，預測期內年複合成長率為6.9%。

Capecitabine化療藥物用於治療多種癌症，包括腹部癌、大腸和乳癌。它以商品名 XelodaCapecitabine 市售，用作乳腺癌的單一療法或轉移性疾病的治療，而對於大腸，它通常與放射線治療聯合用作新輔助療法。它以其有效性、相對可控的副作用以及在提高與各種癌症作鬥爭的人們的生存率和生活品質方面的作用而聞名。

根據美國癌症協會的報告，2017年美國有約135,430例大腸直腸癌新患者和50,260例死亡。

癌症患者增加

Capecitabine是一種化療藥物，廣泛用於治療多種癌症類型，包括乳癌、大腸和胃癌。口服Capecitabine，加上其在體內轉化為活性形式的能力，使其成為一種方便而有效的癌症治療選擇。癌症患者人數不斷增加，需要增加Capecitabine等治療方案的可及性，導致市場成長，作為應對全球癌症患者不斷成長趨勢的重要治療方案。

治療費用增加

隨著包括藥品成本在內的醫療保健成本的增加，負擔能力已成為患者和醫療保健系統關注的問題。Capecitabine是一種用於治療多種癌症的化療藥物，價格昂貴且難以獲得，這可能會影響患者的醫囑遵從性和醫療保健預算限制。個人和醫療保健提供者日益增加的經濟負擔可能會限制這種藥物的獲得，阻礙其普及，並影響癌症患者的治療選擇。

擴大口服化療的接受度

作為一種口服藥物，與標準靜脈注射相比，Capecitabine在治療期間為患者提供了更大的便利性、彈性，並提高了生活品質。此外，它需要最少的醫院就診次數，並且可以在家中自行管理，簡化了醫療服務並降低了成本。此外，癌症治療中向口服化療的轉變代表了一種進化的變化。Capecitabine是一種口服製劑，引領了這一趨勢，並透過滿足患者對更方便、更容易獲得的治療選擇的需求而在市場上立足。這將促進市場成長。

缺乏熟練的專業人員

化療，包括Capecitabine等藥物，需要專門的知識和訓練。缺乏熟練的腫瘤科醫生、護士和藥劑師來管理和監督化療可能會阻礙Capecitabine的有效使用和處方。缺乏熟練的專業人員可能會導致治療效果不佳、損害患者的治療效果並限制藥物的供應。

COVID-19 的影響

COVID-19 大流行對整個經濟產生了顯著影響。受疫情影響，多家原料藥生產廠關閉，原料藥業務面臨許多挑戰。其中包括供應鏈中斷、原料和包裝材料採購問題以及勞動力短缺導致的營運能力下降。然而，隨著COVID-19情勢的惡化，幾種藥品的市場激增，增加了對生產相關活性原料藥的需求。

預計乳癌細分市場在預測期內將是最大的

據估計，乳癌所佔比例最大。Capecitabine是一種口服化療藥物，廣泛用於治療各個階段和類型的乳癌，包括轉移性乳癌和手術後的輔助性治療。由於其有效抑制癌細胞增生且口服給藥方便，成為乳癌治療方法的首選。作為聯合治療或單一療法的一部分，Capecitabine在靶向乳癌細胞方面的功效已經確立了其重要性，並鞏固了其作為滿足乳癌患者治療需求的關鍵組成部分的地位。

預計膠囊細分市場在預測期內年複合成長率最高。

預計膠囊細分市場在預測期內將出現良好的成長。Capecitabine通常以膠囊形式提供，為接受化療的患者提供了方便的口服給藥途徑。膠囊含有活性藥物，可以精確劑量且易於攝取。此外，Capecitabine的膠囊型態為醫療保健專業人員和患者提供了一種方便有效的治療各種癌症的選擇，進一步鞏固了其在製藥行業的地位，這大幅有助於我們在市場上的佔有率。

佔有率最大的地區

由於癌症的流行和弱勢老年人口，亞太地區在預測期內佔據了最大的市場佔有率。此外，龐大的人口基數，尤其是中國、印度和日本等國家，擁有大量患者，推動市場擴張。此外，製藥公司之間的合作夥伴關係，政府加強癌症治療的舉措以及具有成本效益的學名藥的推出進一步支持了Capecitabine在亞太地區的供應和普及。

年複合成長率最高的地區：

北美是主要非專利藥公司的所在地，由於政府舉措和特殊社區的增加，預計在預測期內將實現報酬率成長。此外，該地區強大的醫療基礎設施、先進的研究設施和高癌症發病率促使Capecitabine在治療各種癌症類型（包括乳癌和大腸）中得到大量使用。有利的償付政策和醫療保健投資的增加支持了Capecitabine的可及性，使北美成為塑造Capecitabine利用和市場擴張格局的關鍵地區。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球Capecitabine市場：依藥物類型

  • 非專利
  • 品牌

第6章 全球Capecitabine市場：依適應症分類

  • 乳癌
  • 大腸直腸癌
  • 其他適應症

第7章 全球Capecitabine市場：按分銷管道

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章 全球Capecitabine市場：按劑型

  • 膠囊
  • 藥片

第9章 Capecitabine全球市場：依最終用戶分類

  • 醫院
  • 專業中心
  • 居家護理
  • 其他最終用戶

第10章 全球Capecitabine市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司簡介

  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan NV
  • Sanofi
  • GSK plc
  • Pfizer Inc.
  • Novartis AG
  • Lilly
  • Bayer AG
  • Merck & Co., Inc.
  • Aurobindo Pharma
  • Sun Pharmaceutical Industries Ltd.
  • Alkem Labs Ltd
  • Lupin
  • Armas Pharmaceuticals, Inc
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Inc.
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Limited
Product Code: SMRC24733

According to Stratistics MRC, the Global Capecitabine Market is accounted for $ 436.36 million in 2023 and is expected to reach $ 696.13 million by 2030 growing at a CAGR of 6.9% during the forecast period. A chemotherapy drug called capecitabine is used to treat a variety of cancers, such as abdomen, colorectal, and breast cancers. It is commercialized under the trade name of XelodaCapecitabine is used as a monotherapy or metastatic treatment for breast cancer, while in cases of colorectal cancer, the drug is mostly used as neoadjuvant therapy with radiation. It is known for its efficacy, relatively manageable side effects, and its role in improving survival rates and quality of life for individuals battling various forms of cancer.

According to the American Cancer Society report, in 2017 about 135,430 new cases and 50,260 deaths were estimated due to colon and rectum cancer in the U.S.

Market Dynamics:

Driver:

Rising in cancer cases

Capecitabine, a chemotherapy medication, is widely used in the treatment of multiple cancer types, including breast, colorectal, and gastric cancers. Its oral administration, coupled with its ability to convert into an active form within the body, makes it a convenient and potent option for cancer therapy. The expanding pool of cancer patients necessitates increased access to treatment options like Capecitabine, thereby driving its market growth as a crucial therapeutic choice in combating the rising tide of cancer cases worldwide.

Restraint:

Increasing treatment costs

As healthcare expenses rise, including medication costs, affordability becomes a concern for patients and healthcare systems. Capecitabine, a chemotherapy drug used to treat various cancers, might become less accessible due to its higher cost, impacting patient adherence and healthcare budget constraints. The increasing financial burden on individuals and healthcare providers limits access to this medication, potentially hindering its widespread use and affecting treatment options for cancer patients.

Opportunity:

Growing acceptance of oral chemotherapy

As an oral medication, capecitabine offers patients more convenience, flexibility, and a better quality of life throughout treatment than standard intravenous chemotherapy. In addition, minimal hospital visits are required, and self-administration at home is an option, which simplifies healthcare delivery and lowers expenses. Moreover, the change in cancer treatment towards oral chemotherapy is indicative of an evolutionary change. Capecitabine, with its oral formulation, is leading this trend and has positioned itself well in the market by satisfying patient demand for more convenient and accessible treatment alternatives. Thereby, it will enhance market growth.

Threat:

Lack of Skilled Professionals

Administering chemotherapy, including drugs like Capecitabine, requires specialised knowledge and training. The shortage of proficient oncologists, nurses, and pharmacists capable of managing and overseeing chemotherapy procedures could impede the effective use and prescription of Capecitabine. This dearth of skilled professionals might result in suboptimal treatment, compromising patient outcomes, and potentially limiting the drug's utilization.

COVID-19 Impact

The COVID-19 pandemic had a notable effect on the overall economy. The pandemic caused many API manufacturing plants to close during this time, which presented the API business with a number of difficulties. Some of these were supply chain disruptions, issues in locating raw materials and packaging materials, and decreased operational capacity as a result of labour shortages. But when the COVID-19 situation worsened, there was a surge in the market for several medications, which raised the need for production-related APIs.

The breast cancer segment is expected to be the largest during the forecast period

The breast cancer segment is estimated to hold the largest share. Capecitabine, an oral chemotherapy drug, is widely utilized in various stages and types of breast cancer, including metastatic breast cancer and adjuvant therapy after surgery. Its effectiveness in inhibiting cancer cell growth and its oral administration convenience make it a preferred choice in breast cancer treatment regimens. As part of combination therapies or standalone treatment, Capecitabine's efficacy in targeting breast cancer cells has established its significance, cementing its position as a pivotal component in addressing the therapeutic needs of patients battling breast cancer.

The capsules segment is expected to have the highest CAGR during the forecast period

The capsules segment is anticipated to have lucrative growth during the forecast period. Capecitabine is commonly available in capsule form, offering a convenient oral administration route for patients undergoing chemotherapy. The capsules contain the active drug, facilitating precise dosing and ease of intake. Moreover, the capsule form of Capecitabine contributes substantially to its market presence, providing both medical professionals and patients with a convenient and efficient option for managing various cancer types, further solidifying its role in the pharmaceutical landscape.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to the prevalence of cancer and vulnerable geriatric population. Additionally, the region's large population base, particularly in countries like China, India, and Japan, offers a substantial patient pool, fostering market expansion. Moreover, collaborations between pharmaceutical companies, government initiatives to enhance cancer care, and the introduction of cost-effective generic versions further propel the accessibility and adoption of Capecitabine across the Asia-Pacific region.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period due to the presence of key generic pharmaceutical companies in this region and the rise in government initiatives and special communities. Moreover, the region's robust healthcare infrastructure, advanced research facilities, and high prevalence of cancer contribute to the substantial utilisation of Capecitabine in the treatment of various cancer types, including breast and colorectal cancers. Favourable reimbursement policies and increasing investments in healthcare support the accessibility of Capecitabine, making North America a pivotal region in shaping the landscape of Capecitabine utilisation and market expansion.

Key players in the market:

Some of the key players in the Capecitabine Market include F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi, GSK plc, Pfizer Inc., Novartis AG, Lilly, Bayer AG, Merck & Co., Inc., Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Alkem Labs Ltd, Lupin, Armas Pharmaceuticals, Inc, Dr. Reddy's Laboratories Ltd., Cipla Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC and Intas Pharmaceuticals Limited.

Key Developments:

In December 2022, Shilpa Medicare announced that it has introduced Capecitabine (Capebel) dispersible tablet (DT) with technology of faster dispersion within 90 seconds to treat colorectal and metastatic breast cancer. This product launch may help the company to enhance their product portfolio and enhance business revenue.

In February 2021, Dr Reddy's Laboratories announced the launch of Capecitabine Tablets, USP, in the U.S. market. The product is a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration (USFDA). This product launch helped the company to enhance their product portfolio and enhance their business revenue.

Drug Types Covered:

  • Generic
  • Branded

Indications Covered:

  • Breast Cancer
  • Colorectal Cancer
  • Other Indications

Distribution Channels Covered:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Drug Formulations Covered:

  • Capsules
  • Tablets

End Users Covered:

  • Hospitals
  • Speciality Centres
  • Homecare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Capecitabine Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Generic
  • 5.3 Branded

6 Global Capecitabine Market, By Indication

  • 6.1 Introduction
  • 6.2 Breast Cancer
  • 6.3 Colorectal Cancer
  • 6.4 Other Indications

7 Global Capecitabine Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacy
  • 7.3 Retail Pharmacy
  • 7.4 Online Pharmacy

8 Global Capecitabine Market, By Drug Formulation

  • 8.1 Introduction
  • 8.2 Capsules
  • 8.3 Tablets

9 Global Capecitabine Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Speciality Centres
  • 9.4 Homecare
  • 9.5 Other End Users

10 Global Capecitabine Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 F. Hoffmann-La Roche Ltd.
  • 12.2 Teva Pharmaceutical Industries Ltd.
  • 12.3 Mylan N.V.
  • 12.4 Sanofi
  • 12.5 GSK plc
  • 12.6 Pfizer Inc.
  • 12.7 Novartis AG
  • 12.8 Lilly
  • 12.9 Bayer AG
  • 12.10 Merck & Co., Inc.
  • 12.11 Aurobindo Pharma
  • 12.12 Sun Pharmaceutical Industries Ltd.
  • 12.13 Alkem Labs Ltd
  • 12.14 Lupin
  • 12.15 Armas Pharmaceuticals, Inc
  • 12.16 Dr. Reddy's Laboratories Ltd.
  • 12.17 Cipla Inc.
  • 12.18 Fresenius SE & Co. KGaA
  • 12.19 Hikma Pharmaceuticals PLC
  • 12.20 Intas Pharmaceuticals Limited

List of Tables

  • Table 1 Global Capecitabine Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Capecitabine Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 3 Global Capecitabine Market Outlook, By Generic (2021-2030) ($MN)
  • Table 4 Global Capecitabine Market Outlook, By Branded (2021-2030) ($MN)
  • Table 5 Global Capecitabine Market Outlook, By Indication (2021-2030) ($MN)
  • Table 6 Global Capecitabine Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 7 Global Capecitabine Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 8 Global Capecitabine Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 9 Global Capecitabine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 10 Global Capecitabine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 11 Global Capecitabine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 12 Global Capecitabine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 13 Global Capecitabine Market Outlook, By Drug Formulation (2021-2030) ($MN)
  • Table 14 Global Capecitabine Market Outlook, By Capsules (2021-2030) ($MN)
  • Table 15 Global Capecitabine Market Outlook, By Tablets (2021-2030) ($MN)
  • Table 16 Global Capecitabine Market Outlook, By End User (2021-2030) ($MN)
  • Table 17 Global Capecitabine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 18 Global Capecitabine Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 19 Global Capecitabine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 20 Global Capecitabine Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 21 North America Capecitabine Market Outlook, By Country (2021-2030) ($MN)
  • Table 22 North America Capecitabine Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 23 North America Capecitabine Market Outlook, By Generic (2021-2030) ($MN)
  • Table 24 North America Capecitabine Market Outlook, By Branded (2021-2030) ($MN)
  • Table 25 North America Capecitabine Market Outlook, By Indication (2021-2030) ($MN)
  • Table 26 North America Capecitabine Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 27 North America Capecitabine Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 28 North America Capecitabine Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 29 North America Capecitabine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 30 North America Capecitabine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 31 North America Capecitabine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 32 North America Capecitabine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 33 North America Capecitabine Market Outlook, By Drug Formulation (2021-2030) ($MN)
  • Table 34 North America Capecitabine Market Outlook, By Capsules (2021-2030) ($MN)
  • Table 35 North America Capecitabine Market Outlook, By Tablets (2021-2030) ($MN)
  • Table 36 North America Capecitabine Market Outlook, By End User (2021-2030) ($MN)
  • Table 37 North America Capecitabine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 38 North America Capecitabine Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 39 North America Capecitabine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 40 North America Capecitabine Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 41 Europe Capecitabine Market Outlook, By Country (2021-2030) ($MN)
  • Table 42 Europe Capecitabine Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 43 Europe Capecitabine Market Outlook, By Generic (2021-2030) ($MN)
  • Table 44 Europe Capecitabine Market Outlook, By Branded (2021-2030) ($MN)
  • Table 45 Europe Capecitabine Market Outlook, By Indication (2021-2030) ($MN)
  • Table 46 Europe Capecitabine Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 47 Europe Capecitabine Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 48 Europe Capecitabine Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 49 Europe Capecitabine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 50 Europe Capecitabine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 51 Europe Capecitabine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 52 Europe Capecitabine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 53 Europe Capecitabine Market Outlook, By Drug Formulation (2021-2030) ($MN)
  • Table 54 Europe Capecitabine Market Outlook, By Capsules (2021-2030) ($MN)
  • Table 55 Europe Capecitabine Market Outlook, By Tablets (2021-2030) ($MN)
  • Table 56 Europe Capecitabine Market Outlook, By End User (2021-2030) ($MN)
  • Table 57 Europe Capecitabine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 58 Europe Capecitabine Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 59 Europe Capecitabine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 60 Europe Capecitabine Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 61 Asia Pacific Capecitabine Market Outlook, By Country (2021-2030) ($MN)
  • Table 62 Asia Pacific Capecitabine Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 63 Asia Pacific Capecitabine Market Outlook, By Generic (2021-2030) ($MN)
  • Table 64 Asia Pacific Capecitabine Market Outlook, By Branded (2021-2030) ($MN)
  • Table 65 Asia Pacific Capecitabine Market Outlook, By Indication (2021-2030) ($MN)
  • Table 66 Asia Pacific Capecitabine Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 67 Asia Pacific Capecitabine Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 68 Asia Pacific Capecitabine Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 69 Asia Pacific Capecitabine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 70 Asia Pacific Capecitabine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 71 Asia Pacific Capecitabine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 72 Asia Pacific Capecitabine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 73 Asia Pacific Capecitabine Market Outlook, By Drug Formulation (2021-2030) ($MN)
  • Table 74 Asia Pacific Capecitabine Market Outlook, By Capsules (2021-2030) ($MN)
  • Table 75 Asia Pacific Capecitabine Market Outlook, By Tablets (2021-2030) ($MN)
  • Table 76 Asia Pacific Capecitabine Market Outlook, By End User (2021-2030) ($MN)
  • Table 77 Asia Pacific Capecitabine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 78 Asia Pacific Capecitabine Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 79 Asia Pacific Capecitabine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 80 Asia Pacific Capecitabine Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 81 South America Capecitabine Market Outlook, By Country (2021-2030) ($MN)
  • Table 82 South America Capecitabine Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 83 South America Capecitabine Market Outlook, By Generic (2021-2030) ($MN)
  • Table 84 South America Capecitabine Market Outlook, By Branded (2021-2030) ($MN)
  • Table 85 South America Capecitabine Market Outlook, By Indication (2021-2030) ($MN)
  • Table 86 South America Capecitabine Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 87 South America Capecitabine Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 88 South America Capecitabine Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 89 South America Capecitabine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 90 South America Capecitabine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 91 South America Capecitabine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 92 South America Capecitabine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 93 South America Capecitabine Market Outlook, By Drug Formulation (2021-2030) ($MN)
  • Table 94 South America Capecitabine Market Outlook, By Capsules (2021-2030) ($MN)
  • Table 95 South America Capecitabine Market Outlook, By Tablets (2021-2030) ($MN)
  • Table 96 South America Capecitabine Market Outlook, By End User (2021-2030) ($MN)
  • Table 97 South America Capecitabine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 98 South America Capecitabine Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 99 South America Capecitabine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 100 South America Capecitabine Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 101 Middle East & Africa Capecitabine Market Outlook, By Country (2021-2030) ($MN)
  • Table 102 Middle East & Africa Capecitabine Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 103 Middle East & Africa Capecitabine Market Outlook, By Generic (2021-2030) ($MN)
  • Table 104 Middle East & Africa Capecitabine Market Outlook, By Branded (2021-2030) ($MN)
  • Table 105 Middle East & Africa Capecitabine Market Outlook, By Indication (2021-2030) ($MN)
  • Table 106 Middle East & Africa Capecitabine Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 107 Middle East & Africa Capecitabine Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 108 Middle East & Africa Capecitabine Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 109 Middle East & Africa Capecitabine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 110 Middle East & Africa Capecitabine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 111 Middle East & Africa Capecitabine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 112 Middle East & Africa Capecitabine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 113 Middle East & Africa Capecitabine Market Outlook, By Drug Formulation (2021-2030) ($MN)
  • Table 114 Middle East & Africa Capecitabine Market Outlook, By Capsules (2021-2030) ($MN)
  • Table 115 Middle East & Africa Capecitabine Market Outlook, By Tablets (2021-2030) ($MN)
  • Table 116 Middle East & Africa Capecitabine Market Outlook, By End User (2021-2030) ($MN)
  • Table 117 Middle East & Africa Capecitabine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 118 Middle East & Africa Capecitabine Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 119 Middle East & Africa Capecitabine Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 120 Middle East & Africa Capecitabine Market Outlook, By Other End Users (2021-2030) ($MN)